PA
RCUS icon

Parallel Advisors’s Arcus Biosciences RCUS Stock Holding History

Parallel Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.67M Hold
86,557
– – 0.04% 272
2026
Q1 		$1.87M Hold
86,557
– – 0.03% 314
2025
Q4 		$2.06M Sell
86,557
-1,450
-2% -$29.6K 0.04% 290
2025
Q3 		$1.2M Hold
88,007
– – 0.02% 383
2025
Q2 		$716K Buy
88,007
+1,422
+2% +$12.1K 0.01% 524
2025
Q1 		$706K Buy
86,585
+778
+0.9% +$9.02K 0.02% 483
2024
Q4 		$1.28M Hold
85,807
– – 0.03% 333
2024
Q3 		$1.31M Sell
85,807
-15
-0% -$237 0.03% 329
2024
Q2 		$1.31M Buy
85,822
+15
+0% +$242 0.03% 304
2024
Q1 		$1.62M Buy
85,807
+75
+0.1% +$1.3K 0.04% 264
2023
Q4 		$1.64M Buy
85,732
+350
+0.4% +$5.59K 0.05% 241
2023
Q3 		$1.53M Hold
85,382
– – 0.05% 229
2023
Q2 		$1.73M Hold
85,382
– – 0.06% 224
2023
Q1 		$1.56M Buy
85,382
+225
+0.3% +$4.3K 0.05% 239
2022
Q4 		$1.76M Buy
85,157
+295
+0.3% +$8.12K 0.08% 172
2022
Q3 		$2.22M Buy
84,862
+5
+0% +$132 0.1% 133
2022
Q2 		$2.15M Buy
84,857
+29
+0% +$710 0.1% 138
2022
Q1 		$2.83M Buy
84,828
+25
+0% +$838 0.11% 127
2021
Q4 		$3.43M Sell
84,803
-180
-0.2% -$6.98K 0.13% 116
2021
Q3 		$2.96M Sell
84,983
-242
-0.3% -$7.53K 0.12% 130
2021
Q2 		$2.34M Hold
85,225
– – 0.1% 146
2021
Q1 		$2.39M Hold
85,225
– – 0.11% 134
2020
Q4 		$2.21M Hold
85,225
– – 0.12% 132
2020
Q3 		$1.46M Sell
85,225
-1,655
-2% -$37K 0.09% 154
2020
Q2 		$2.15M Sell
86,880
-734
-0.8% -$19.8K 0.14% 115
2020
Q1 		$1.22M Buy
87,614
+759
+0.9% +$9.44K 0.1% 142
2019
Q4 		$877K Buy
86,855
+800
+0.9% +$6.73K 0.07% 200
2019
Q3 		$783K Buy
86,055
+85,430
+13,669% +$686K 0.07% 198
2019
Q2 		$5K Buy
+625
New +$6.26K ﹤0.01% 1844

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Parallel Advisors's RCUS Position: Q2 2026 in Review

Parallel Advisors held its Arcus Biosciences (RCUS) position steady in Q2 2026 at 86,557 shares worth $2.67M. The position accounts for 0.04% of the portfolio, ranked #272.

Parallel Advisors first reported a position in RCUS in Q2 2019 and has held it in 29 quarters since. The position peaked at $3.43M in Q4 2021. 72 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Parallel Advisors held 86,557 shares of Arcus Biosciences worth $2.67M as of Q2 2026.
  • Parallel Advisors left its Arcus Biosciences share count unchanged in Q2 2026.
  • Arcus Biosciences made up 0.04% of Parallel Advisors's portfolio in Q2 2026, its #272 holding.
  • Parallel Advisors first reported a position in Arcus Biosciences in Q2 2019 and has held it in 29 quarters since.
  • Parallel Advisors's Arcus Biosciences position peaked at $3.43M in Q4 2021.
  • 72 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.